Also known as: Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and licensing technologies and assets that support partner drug development. Its model emphasizes royalty and milestone revenue from partnered programs.
Arecor said it is in talks on a broader AT278 partnership as it targets a phase II trial start in the second half of 2026. The company also cited FDA feedback, Ligand financing and year-end cash of £6.1 million.
Ligand Pharmaceuticals will release Q4 and full year 2025 financial results on February 26, 2026, following recent share price declines despite strong annual returns. The company reported annual revenue of $251.233 million and net income of $48.581 million.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00238628 |
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer |
COMPLETED | PHASE1/PHASE2 |
